1. Introduction {#sec1-ijms-21-01582}
===============

Osteoarthritis (OA) is a heterogeneous disease with a wide range of underlying pathways and involves structural alterations mainly in the articular cartilage, subchondral bone and synovial membrane \[[@B1-ijms-21-01582]\]. In particular, OA is characterized by a complex biological imbalance between the repair and destruction of joint tissues, rather than a stand-alone mechanical degeneration \[[@B2-ijms-21-01582]\]. The initial loss of cartilage integrity leads first to superficial erosions and later to fissures followed by the expansion of calcifications. Matrix degradation products and proinflammatory mediators deregulate chondrocyte function and stimulate synovium proliferative and inflammatory responses of both resident synoviocytes and macrophages. Eventually, bone turnover is increased with the development of subchondral bone marrow lesions \[[@B3-ijms-21-01582]\].

Due to the strong biological fingerprint, the ideal OA management should rely on the restoration of tissue homeostasis. Nevertheless, to date, available treatments are not supposed to have a direct influence on the damaged tissues but, rather, on symptoms control. Oral nonsteroidal anti-inflammatory and analgesic drugs, as well as intra-articular corticosteroids or hyaluronic acid (HA), are commonly used alone or in combination to manage early pain and improve mobility \[[@B4-ijms-21-01582]\]. In end-stage OA, joint replacement is still the most effective practice \[[@B5-ijms-21-01582],[@B6-ijms-21-01582]\]. Nevertheless, although total knee replacement showed greater pain relief and functional improvement than nonsurgical treatments \[[@B7-ijms-21-01582]\], up to 25% of patients still complain of pain and disability after surgery \[[@B8-ijms-21-01582]\]. In this perspective, new biological-based products aimed to prevent the progression of OA and restoring tissue homeostasis have been introduced. They are mostly based on mesenchymal stem cells (MSCs) whose pro-regenerative properties are well known. Of note, in addition to expanded MSCs, MSC-enriched products prepared at the point of care under minimal manipulation are also available, both from bone marrow (bone marrow aspirate concentrate---BMAC) and adipose tissue (stromal vascular fraction---SVF or microfragmented fat tissue---MFAT).

MSCs are multipotent cells with a high capacity for self-renewal that, in adult life, are found dormant in vivo as pericytes and, once activated, take part in tissue repair \[[@B9-ijms-21-01582]\]. Further, signals associated with disease, such as pro-inflammatory mediators in the joint cavity, may enhance MSCs activity, which in turn secrete factors, chemokines and cytokines able to limit the extent of damage and improve tissue healing \[[@B10-ijms-21-01582]\]. In this frame, both in vitro and in vivo, MSCs were shown to secrete an array of molecules with, among others, anti-inflammatory properties, such as: prostaglandin-E2 (PGE2), responsible for inducing an M2 switch in human synovial macrophages \[[@B11-ijms-21-01582]\]; indoleamine 2,3-dioxygenase (IDO), suppressing T-cell proliferation \[[@B12-ijms-21-01582]\] and driving M2 polarization of macrophages \[[@B13-ijms-21-01582]\] and other anti-inflammatory and immunosuppressive molecules, like iNOS, TSG6, HO1, TGF-β and galectins \[[@B14-ijms-21-01582]\]. Supporting this notion, both MSCs and MSC-conditioned mediums (CMs) have been shown to have a protective effect on cartilage in a murine OA model, together with pain reduction \[[@B15-ijms-21-01582]\], the last due to a decrement of inflammation, as also shown in both in vitro models of OA chondrocyte \[[@B16-ijms-21-01582]\] and ex vivo explants of cartilage and synovia \[[@B17-ijms-21-01582]\]. In fact, together with cartilage destruction, inflammation is a crucial player in the establishment and maintenance of OA and positively correlates with knee pain \[[@B18-ijms-21-01582]\], with synovial membrane inflammation a hallmark of the pathology \[[@B19-ijms-21-01582]\]. Moreover, higher levels of pro-inflammatory cytokines and infiltrated immune cells, predominantly macrophages, positively correlate with OA severity \[[@B20-ijms-21-01582]\].

Together with secreted factors, in the last years, it has been proposed that also extracellular vesicles (EVs) and embedded molecules, such as proteins, lipids or nucleic acids (predominantly miRNAs), may contribute to MSC pro-regenerative and immunosuppressive potential \[[@B21-ijms-21-01582],[@B22-ijms-21-01582]\]. In OA, preliminary in vitro results showed MSC-EVs protective effects on both chondrocytes and synoviocytes \[[@B23-ijms-21-01582],[@B24-ijms-21-01582]\]. Notably, EVs derived from synovial MSCs overexpressing miR-140-5p induced proliferation of chondrocytes in vitro, supporting the crucial role of miRNAs \[[@B25-ijms-21-01582]\]. Consistently, in an OA mouse model, synovium MSC-EVs attenuated disease scores by promoting chondrocyte proliferation and migration \[[@B26-ijms-21-01582]\]. Similar results were obtained with EVs obtained from ASCs, bone marrow- and amniotic fluid-derived MSCs, with an almost complete restoration of cartilage, less pain and a M1 to M2 polarization of macrophages \[[@B27-ijms-21-01582],[@B28-ijms-21-01582],[@B29-ijms-21-01582]\]. In this frame, MSC-EVs have been demonstrated to possess regulatory functions on immune cells by regulating the proliferation, maturation, polarization and migration of various immune effector cells \[[@B30-ijms-21-01582]\]. As an example, in a model of collagen-induced OA, MSC-EVs exerted anti-inflammatory effects through the inhibition of B cell maturation \[[@B27-ijms-21-01582]\]. Moreover, an increasing number of reports showed the M1-suppressing and M2-enhancing capacities of MSC-EVs on macrophages, mainly through shuttled miRNAs \[[@B30-ijms-21-01582]\], contributing to the beneficial effect of ASCs on macrophage regulation \[[@B31-ijms-21-01582]\]. Intriguingly, also MFAT was shown to switch off synovial macrophage activity in vitro \[[@B32-ijms-21-01582]\], through a decrease of activating chemokines and, possibly, the presence of M2-modulating EVs.

Therefore, a complex network of both soluble factors and EVs-embedded miRNAs would be responsible for the promising results of MSC-based therapies in the OA setting. Nevertheless, to date, a complete picture of secreted molecules and miRNAs is missing, especially in conditions mimicking those MSCs find once injected in the OA joint. In fact, often, the experimentally induced inflammatory conditions are very far from the real amount and types of inflammatory factors found in a pathological joint. The aim of this study was therefore to identify secreted cytokines, chemokines and growth factors and EV-shuttled miRNAs from ASCs treated with inflammatory mediators at concentrations resembling those in the OA synovial fluid based on literature reports \[[@B33-ijms-21-01582],[@B34-ijms-21-01582],[@B35-ijms-21-01582],[@B36-ijms-21-01582],[@B37-ijms-21-01582],[@B38-ijms-21-01582],[@B39-ijms-21-01582],[@B40-ijms-21-01582],[@B41-ijms-21-01582]\] in order to clarify how the ASCs regulate cell homeostasis and regenerative pathways in OA joints.

2. Results {#sec2-ijms-21-01582}
==========

2.1. ASCs Characterization {#sec2dot1-ijms-21-01582}
--------------------------

ASCs were characterized by flow cytometry for both MSCs and hemato-endothelial markers in the absence and presence of OA-resembling cytokines TNFα (5 pg/mL) + IL1β (10 pg/mL) + IFNγ (40 pg/mL), with working concentrations obtained by calculating the median values from the OA synovial fluid analysis \[[@B33-ijms-21-01582],[@B34-ijms-21-01582],[@B35-ijms-21-01582],[@B36-ijms-21-01582],[@B37-ijms-21-01582],[@B38-ijms-21-01582],[@B39-ijms-21-01582],[@B40-ijms-21-01582],[@B41-ijms-21-01582]\] ([Figure 1](#ijms-21-01582-f001){ref-type="fig"}A). The cells were strongly positive for mesenchymal epitopes ([Figure 1](#ijms-21-01582-f001){ref-type="fig"}B, CD90-CD73-CD44) and negative for CD31, CD34 and CD45, confirming their identity ([Figure 1](#ijms-21-01582-f001){ref-type="fig"}C). Inflammation did not alter marker expression, as well as viability (95% ± 1% in control ASCs and 96% ± 1% in the OA condition).

2.2. ASCs Secreted Factors {#sec2dot2-ijms-21-01582}
--------------------------

Two hundred molecules, including inflammatory mediators and growth factors, chemokines, receptors and cytokines, were tested in conditioned medium produced by ASCs under OA-simulating conditions. Seventy-five molecules were scored in all samples at 48 h of induction ([Table 1](#ijms-21-01582-t001){ref-type="table"}). Interestingly, about 0.2 ng of IL1β and TNFα were detected. This value is higher than the initial levels in the culture medium provided by the medium supplementation (0.01 and 0.05, respectively). On the other side, IFNγ was below detection, meaning a consumption of the administered cytokine without further release given by inflammation at the selected time point of 48 h, being aware that a more prolonged inflammation might lead to its secretion. Hierarchical clustering was able to show a higher similarity for ASC 1 and 3 ([Figure 2](#ijms-21-01582-f002){ref-type="fig"}), although in a pattern of overall conservation, since the correlation analysis showed a mean R^2^ of 0.96 ± 0.02. Consequently, an average intensity value was calculated in order to provide a guide to the level of each factor ([Table 1](#ijms-21-01582-t001){ref-type="table"}). In 48 h, per million cells, four factors were secreted with an average amount superior to 100 ng, namely FST (mean 1037 ± SD 377), TIMP2 (196 ± 43), IGFBP4 (182 ± 85) and SERPINE1 (108 ± 9). Fourteen factors were between 10 and 100 ng: IGFBP6 (86 ± 7), IL6ST (56 ± 15), CTSS (52 ± 10), IL6 (49 ± 23), TIMP1 (34 ± 6), ICAM 1 (27 ± 5), CXCL10 (26 ± 10), IL2RB (24 ± 5), TNFRSF1A (18 ± 4), CCL2 (16 ± 2), PLG (16 ± 2), CXCL5 (16 ± 15), DKK1 (12 ± 4) and PI3 (12 ± 9). Eventually, the average amount of 24 factors was between 10 and 1 ng and, of the other 33, below 1 ng.

Gene ontology enrichment analysis was performed using annotations for the 200 factors as the background dataset. Two groups were scored: (i) the 18 factors with an amount \> than 10 ng, representing a more focused and preponderant secretome fingerprint and (ii) the factors secreted at lower levels that, even if less abundant, could represent an equally important overall signal due to higher number of molecules. For heavily secreted factors, gene ontology (GO) enrichment analysis identified two significant (*p*-value \< 10^−3^) biological process (BP) terms, namely cellular component disassembly (GO:0022411), encompassed by five proteins, and extracellular matrix disassembly (GO:0022617), defined by four players ([Figure 3](#ijms-21-01582-f003){ref-type="fig"}A and [Table 2](#ijms-21-01582-t002){ref-type="table"}). When the other 57 factors were analyzed, eight statistically enriched BPs were found ([Figure 3](#ijms-21-01582-f003){ref-type="fig"}B and [Table 2](#ijms-21-01582-t002){ref-type="table"}), with the terminal nodes being for the: (i) biological regulation pathway---regulation of anatomical structure morphogenesis (GO:0022603, 28 molecules), regulation of symbiosis, encompassing mutualism through parasitism (GO:0043903, seven) and regulation of protein secretion (GO:0050708, 19) and, for the (ii) response to stimulus cascade---inflammatory response (GO:0006954, 31). Further, due to the reported role of ASCs in modulating synovial macrophages, the inflammatory response list was sifted through a Panther algorithm to identify specific and macrophage-related GO terms. A few terms emerged: macrophage chemotaxis (GO:0048246, two factors) and migration (GO:1905517), both defined by CCL3 and CCL5; the positive regulation of macrophage differentiation (GO:0045651) and regulation of macrophage differentiation (GO:0045649), both defined by CSF1 and TGFB1; the positive regulation of macrophage chemotaxis (GO:0010759, CCL5 and CSF1) and regulation of macrophage chemotaxis (GO:0010758, CSF1, CCL5 and MIF) and the positive regulation of macrophage activation (GO:0043032, CCL3 and IL13) and regulation of macrophage activation (GO:0043030, CCL3, IL13 and MIF). Eventually, to have a comprehensive overview of the entire dataset, in the inflammatory response terms, nine proteins of the \> 10 ng group also fell (CCL2, CXCL10, CXCL5, EGFR, ICAM1, IGFBP4, IL6, TIMP1 and TNFRSF1A). CCL2 belonged to macrophage chemotaxis, LIF to the regulation of macrophage differentiation and IL1RL1 and IL6 to macrophage activation. Related to macrophages and their ability to migrate, monocyte chemotaxis (GO:0002548, IL6 and CCL2) emerged. Interestingly, other GO terms related with motility were identified, like leukocyte chemotaxis (GO:0030595, IL6, CCL2, CXCL5 and CXCL10); lymphocyte chemotaxis (GO:0048247, CCL2 and CXCL10) and granulocyte chemotaxis (GO:0071621, CCL2, CXCL5 and CXCL10). In particular, the positive regulation of leukocyte migration (GO:0002687, ICAM1, IL6 and CXCL10) term was defined, indicating the influence of highly secreted factors on processes that activate or increase the frequency, rate or extent of leukocyte migration. Supporting this notion, a more general analysis of the 65 factors allowed to identify 23 molecules under leukocyte chemotaxis (GO:0030595), with only two factors related to the negative regulation of leukocyte chemotaxis (GO:0002689, MIF and CCL2) and 16 to the positive regulation of leukocyte chemotaxis (GO:0002690). Therefore, overall, ASC secretome was enriched in molecules involved in both extracellular matrix homeostasis and the inflammatory response control to different levels, from migration to homeostasis/activation.

2.3. Characterization of ASC-Derived Extracellular Vesicles {#sec2dot3-ijms-21-01582}
-----------------------------------------------------------

ASCs treated with OA cytokines for 48 h release around 22,500 extracellular vesicles (EVs) per cell. Isolated EVs exhibited the characteristic cup-shape morphology ([Figure 4](#ijms-21-01582-f004){ref-type="fig"}A) and were within the literature-reported size range (50--400 nm in diameter), with enrichment in the small particles (mode 118 ± 19 nm) ([Figure 4](#ijms-21-01582-f004){ref-type="fig"}B). To detect particles within the nanometer range, the flow cytometer has been calibrated with FITC-fluorescent beads of predetermined size (100 to 900 nm, [Figure 4](#ijms-21-01582-f004){ref-type="fig"}C). Purified EVs felt within the 100 nm size, confirming NTA data ([Figure 4](#ijms-21-01582-f004){ref-type="fig"}D). EVs were strongly positive for extracellular vesicle CD63 and CD81 markers ([Figure 4](#ijms-21-01582-f004){ref-type="fig"}E), 78.9% ± 1% and 81.6% ± 0.9%, respectively, consistent with previously reported characteristics of extracellular vesicles. On the contrary, CD9 staining was low (2.4% ± 0.2%).

2.4. EV-Associated miRNAs {#sec2dot4-ijms-21-01582}
-------------------------

Two-hundred and fifty-seven miRNAs were identified as EVs embedded at various levels of expression in all the four ASCs under analysis ([Supplementary Table S1](#app1-ijms-21-01582){ref-type="app"}). EV-miRNA hierarchical clustering output was superimposable to the one obtained for factors with higher similarity for ASC 1 and 3 ([Figure 5](#ijms-21-01582-f005){ref-type="fig"}). Nevertheless, a pattern of overall conservation was again present, with correlation analysis showing a mean R^2^ of 0.97 ± 0.01. Therefore, an average C~RT~ value was calculated in order to provide a guide to the level of each miRNA ([Supplementary Table S1](#app1-ijms-21-01582){ref-type="app"}).

Given the presence on average of one abundant miRNA molecule per EV in MSC, 100 MSC-EVs would be needed to shuttle its genetic message to target cells \[[@B42-ijms-21-01582],[@B43-ijms-21-01582]\]. Therefore, only highly abundant miRNAs laying in the first quartile of expression were considered for further analysis (65 miRNAs, covering 96.7% of the genetic message) ([Supplementary Table S1](#app1-ijms-21-01582){ref-type="app"}, yellow background). Ingenuity pathway analysis (IPA) of the 65 miRNAs used to score only experimentally observed targets identified 818 mRNAs ([Supplementary Table S2](#app1-ijms-21-01582){ref-type="app"}). An unbiased GO enrichment analysis against the whole genome, with a stringent *p*-value threshold (\< 10^−6^) due to the high number of scored mRNAs, was able to identify BP related to cell cycle regulation ([Figure 6](#ijms-21-01582-f006){ref-type="fig"}), with the most significantly (*p*-value \< 10^−9^) enriched terms being: regulation of the cell cycle process (GO:0010564, *p*-value 1.31 × 10^−11^, 45 associated genes) and regulation of the mitotic cell cycle (GO:0007346, 8.14 × 10^−10^, 39 genes). Notably, negative regulation of the cell cycle process term (GO:0010948, 6.12 × 10^−7^, 24 genes) suggested that shuttled miRNAs may reduce the activity of genes delaying the cell cycle events, thus promoting proliferation. To define better this influence, the enriched molecular function (MF) GO search was able to specify target terms as the cyclin-dependent protein serine/threonine kinase regulator activity term (GO:0016538, 2.02 × 10^−9^), encompassing several cyclins (*CCNA2*, *CCNE2*, *CCNF*, *CCNE1*, *CCND1* and *CCND3*); cyclin-dependent kinases (*CDK4*) and inhibitors (*CDKN2A*, *CDKN1C*, *CDKN1B* and *CDKN1A*) and an apoptosis-related cysteine peptidase (*CASP3*).

2.5. Target and Effect Prediction of EV-miRNAs on OA-Cartilage {#sec2dot5-ijms-21-01582}
--------------------------------------------------------------

To frame the power of EV-miRNAs in the OA setting, the 818 target mRNAs were filtered through 2368 abundantly expressed genes, identified as laying in the first quartile of expression (out of 9474 total genes), in cartilage biopsies from OA patients \[[@B44-ijms-21-01582]\]. After filtering, 224 EV-miRNA targets were left and shared ([Supplementary Table S3](#app1-ijms-21-01582){ref-type="app"}). First, identified genes were searched against those in the IPA database of the OA-related pathway. Nineteen genes resulted targets of EV-miRNAs (*ATF4*, *BMPR2*, *FGF2*, *FGFR1*, *FGFR3*, *FN1*, *HIF1A*, *ITGA5*, *JAG1*, *MEF2C*, *MMP3*, *SMAD3*, *SMAD4*, *SMAD5*, *SP1*, *TGFBR1*, *TGFBR2*, *TIMP3* and VEGFA). Most represented protein classes were transcription factors (PC00218: HIF1A, MEF2C, *SMAD3*/4/5 and *SP1*); receptors (PC00197: BMPR2 and TGFBR1/2) and signaling molecules (PC00207: *FGF2*, *FN1* and *VEGFA*). Notably, many of these molecules specified molecular cascades that are directly involved with OA insurgence and development, like TGF-beta (P00052: *BMPR2*, *SMAD3/4/5* and *TGFBR1/2*); FGF (P00021: *FGF2* and *FGFR1/3*) and Wnt (P00057: *SMAD4/5* and *TGFBR1*) signaling pathways. Second, GO enrichment (*p*-value \< 10^−6^ for enriched GO term threshold) was conducted by scoring the 224 mRNAs against the entire first quartile of OA cartilage as background. Several BP terms were identified, suggesting that when a tissue and/or disease-focused search is performed, the specificity and power of the outcomes increase ([Supplementary Figure S1](#app1-ijms-21-01582){ref-type="app"}). In particular, five terms were more significantly enriched (*p*-value \< 10^−9^): the negative regulation of multicellular organismal process (GO:0051241, 1.68 × 10^−10^, 52 genes); regulation of cellular component movement (GO:0051270, 3.93 × 10^−10^, 50 genes); regulation of cell motility (GO:2000145, 4.42 × 10^−10^, 48 genes); cellular response to chemical stimulus (GO:0070887, 7.71 × 10^−10^, 68 genes) and regulation of cell migration (GO:0030334, 8.45 × 10^−10^, 46 genes). Interestingly, EV-miRNAs seem to selectively target genes defining the positive regulation of movement: positive regulation of cell migration (GO:0030335, 1.37 × 10^−9^, 35 genes); positive regulation of cell motility (GO:2000147, 2.76 × 10^−9^, 35 genes) and positive regulation of locomotion (GO:0040017, 6.76 × 10^−9^, 35 genes). All these BP regulating the cell response and adaptation relies on several cascades ending in a complex transcriptional regulation, as outlined by the enriched MF GO term DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981, 1.79 × 10^−8^, 38 genes).

Finally, the list of 65 abundant EV-miRNAs was compared with the database of miRNAs reported to be directly involved in OA pathogenesis, both protective and destructive \[[@B45-ijms-21-01582]\]. Seventeen miRNAs resulted to be involved with protective mechanisms, seven regulate degenerative pathways and four are controlling both mechanisms ([Table 3](#ijms-21-01582-t003){ref-type="table"} and [Figure 7](#ijms-21-01582-f007){ref-type="fig"}). Interestingly, scoring the genetic weight of the EV-shuttle and miRNA-related message, protective molecules account for almost 40%, whereas degenerative ones less than 10%. Overall, this might indicate a preponderance of EV-miRNAs in cartilage and synovium protection.

2.6. Target and Effect Prediction of EV-miRNAs on Synovial Macrophages {#sec2dot6-ijms-21-01582}
----------------------------------------------------------------------

In a recent publication, the transcriptional landscape of infiltrated synovial macrophages has been defined in OA patients \[[@B46-ijms-21-01582]\]. Two types of macrophages were identified: inflammatory-like OA (iOA) macrophages, which are closely aligned to rheumatoid arthritis (RA) macrophages, and classical OA (cOA) ones displaying, together with lower inflammatory features, aberrant tissue repair mechanisms and secretion of factors that may directly contribute to cartilage degradation. Since, in a previous publication, the macrophage transcriptional fingerprint was able to clearly distinguish RA and OA cells \[[@B47-ijms-21-01582]\], we opted to consider newly defined cOA macrophages' mRNA dataset for further analysis. Eight-hundred and eighteen EV-miRNA target mRNAs were filtered against the first quartile of expression (2498 transcripts) of synovial macrophages (total of 9991), and 214 shared genes were identified ([Supplementary Table S4](#app1-ijms-21-01582){ref-type="app"}). Only 112 genes were shared between the OA cartilage and synovial macrophages, suggesting a divergent response.

First, identified genes were searched against those in the IPA database of the inhibition of metalloproteases pathway, a subclass of the previously scored OA pathway, given the role of synovial macrophages in cartilage ECM destruction. Interestingly, *MMP1*, *3* and *9* resulted experimentally verified targets, together with *RECK* and *TIMP3* inhibitors, suggesting a profound role of EVs on OA macrophages remodeling activity. Further, searching the GO term macrophage activation (GO:0042116), out of 94 annotated genes, six emerged as possible targets (*APP*, *IL10*, *JUN*, *TLR4*/7 and *TNFa*). Intriguingly, abundant miRNAs did not target directly the expression of canonical M1 chemokines (CCL2/3/4/8/20 in the top expressed OA-synovial macrophages mRNAs) and cytokines (IL1A/B), with the exception of IL6 and TNFa. On the contrary, EVs might regulate macrophage polarization by targeting TLR4 that, through NF-kb, suppresses STAT3, whose predominance over STAT1 increases M2 polarization, associated with immune tolerance and tissue repairing. Then, to have a more comprehensive view, the genes were scored against the OA synovial-macrophages first quartile mRNAs (*p*-value \< 10^−6^) as background to identify enriched GO terms. Again, several BP emerged, with a completely different pattern with respect to cartilage. In particular, six terms were strongly enriched (*p*-value \< 10^−9^): the anatomical structure development (GO:0048856, 6.05 × 10^−12^, 84 genes); animal organ development (GO:0048513, 3.66 × 10^−11^, 46 genes); positive regulation of multicellular organismal process (GO:0051240, 1.51 × 10^−10^, 68 genes); negative regulation of cell death (GO:0060548, 4.49 × 10^−10^, 54 genes); regulation of smooth muscle cell proliferation (GO:0048660, 7.47 × 10^−10^, 19 genes) and negative regulation of programmed cell death (GO:0043069, 9.95 × 10^−10^, 50 genes). Interestingly, and differently from cartilage, in macrophages, EV-miRNAs may preferentially target genes regulating apoptosis and cell death-related pathways, as emphasized by other significantly enriched GO terms like the negative regulation of the apoptotic process (GO:0043066, 1.47 × 10^−9^, 1.81 × 10^−6^, 49 genes) and regulation of cell death (GO:0010941, 6.29 × 10^−9^, 71 genes). In fact, narrowing the GO enrichment analysis (*p*-value \< 10^−9^ as the threshold for GO enrichment), cell death and its regulation emerged as a main constituent of a GO term branch ([Supplementary Figure S2](#app1-ijms-21-01582){ref-type="app"}). Further, EV-miRNAs are also able to target genes defining myeloid lineage, as shown by GO terms: the regulation of myeloid cell differentiation (GO:0045637, 1.87 × 10^−7^, 19 genes) and positive regulation of myeloid cell differentiation (GO:0045639, 2.04 × 10^−7^, 13 genes). As for cartilage, the different BPs rely on a high number of molecular and transcriptional cascades, as emphasized by the MF GO term DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981, 8.45 × 10^−9^, 31 genes).

Eventually, a database of miRNAs involved in M1 vs. M2 macrophage polarization \[[@B48-ijms-21-01582]\] was scored to weight the influence of embedded EV-miRNAs on macrophage phenotypes ([Table 4](#ijms-21-01582-t004){ref-type="table"}). Although four miRNAs are involved in M2 with respect to seven controlling M1 phenotype, the presence of miR-24-3p, which is responsible for the M1 to M2 switch, and miR-222-3p, which controls M2 polarization, tip the balance towards a more pronounced influence on M2 phenotype ([Figure 8](#ijms-21-01582-f008){ref-type="fig"}). Consistently, as a global EV fingerprint, 26% of first-quartile miRNA-dependent signals are encompassed by M2-related molecules vs. 7% represented by M1 players. Intriguingly, when IPA CCR5 signaling in the macrophages pathway was searched against the 214 target mRNAs, *JUN*, *FOS* and *MAP2K4* kinases were identified, suggesting an EV-dependent downregulation of the CCR5 cascade, whose inactivation resulted in a switch towards an M2 phenotype \[[@B49-ijms-21-01582]\]. Moreover, to support the influence of EV-miRNAs on monocyte/macrophage homeostasis, miR-16-5p (0.5%), regulating the monocyte to macrophage developmental transition, and miR-34a-5p (0.7%) together with miR-132-3p (0.5%), participating in macrophage maturation, were also found in the frame of the most expressed miRNAs.

3. Discussion {#sec3-ijms-21-01582}
=============

In this work, both EV-shuttled miRNAs and soluble factors have been characterized in the secretome of ASCs cultivated in vitro under OA-resembling inflammatory conditions. Several molecules were identified as both cartilage-protective and M1 towards M2 macrophage switchers. Herein presented results provide a strong molecular basis for the promising clinical results observed with ASC-containing products, as MFAT or SVF, in OA settings.

In a murine OA model, injection of MSC secretome, similarly to injection of MSCs, resulted in early pain reduction with a protective effect \[[@B15-ijms-21-01582]\]. Further, both the whole conditioned medium and purified EVs resulted to be effective in cartilage surface restoration and ECM deposition in several in vivo OA defect models \[[@B25-ijms-21-01582],[@B27-ijms-21-01582],[@B50-ijms-21-01582],[@B51-ijms-21-01582],[@B52-ijms-21-01582]\], mainly thorough EV-associated matrix-remodeling enzymes and regulators as a novel means of matrix remodeling in physiological and pathological conditions \[[@B53-ijms-21-01582]\]. In humans, phase I clinical trials demonstrated the safety and preliminary evidence of efficacy and pain reduction by using local injections of autologous ASCs in OA patients \[[@B54-ijms-21-01582],[@B55-ijms-21-01582]\]. Similarly, autologous and minimally manipulated MSC-enriched tissues \[[@B56-ijms-21-01582]\], such as BMAC or MFAT/SVF, showed the same outcomes. Of note, a partially overlapping array of pro-regenerative and anti-inflammatory molecules was recently shown to be secreted from both expanded ASCs and MFAT or lipoaspirates \[[@B57-ijms-21-01582]\], suggesting that signals secreted by MSCs may explain, at least in part, the promising results of MSC-enriched products in OA management.

Although it is quite well-accepted that MSCs act through paracrine mechanisms on resident cells, nevertheless, a thorough characterization of soluble factors and EV content is lacking and would be essential to define MSCs and MSC-enriched products. In this perspective, in the last years, researchers have tried to couple the array of secreted molecules with the observed protective effects in clinical experiences \[[@B58-ijms-21-01582],[@B59-ijms-21-01582]\]. Despite valuable hints, very often, the input datasets had two major flaws. First, secreted factors and EV-miRNAs data were not generated from the same experimental workflow; therefore, technical and/or biological differences were underestimated. Second, for both types of molecules, no inflammatory effects resembling those in the OA joint were considered, being cells cultured in a control medium or under a heavy priming (in the order of ng/mL), which is not close to the concentration of cytokines usually found in synovial fluids (pg/mL). Thus, the present study offers a more homogeneous and comprehensive dataset, being aware that the combination of the three inflammatory cytokines used is a simplified in vitro condition due to the greatly higher number of factors and the wide range of concentration in the joints of OA patients.

Cartilage thinning and degradation are one of the major fingerprints in OA, resulting from an imbalance of the cartilage homeostasis characterized by excessive catabolic activity that overcomes repair capacity. In particular, increased action of the matrix metalloproteinases (MMPs) in combination with reduction of their inhibitors (TIMPs) levels are largely responsible for the earliest osteoarthritic changes \[[@B60-ijms-21-01582]\], suggesting that a restoration of the healthy balance would help in residual cartilage protection and regeneration. Interestingly, in pioneering studies on OA patients, SVF injection was able to stimulate partial regeneration of the articular cartilage, as described by positive changes in the imaging outcomes (MRI or CT) \[[@B61-ijms-21-01582],[@B62-ijms-21-01582],[@B63-ijms-21-01582],[@B64-ijms-21-01582],[@B65-ijms-21-01582]\]. Consistently, in the last years, few clinical trials based on intra-articular injection of autologous ASCs in OA joints reported improvement in pain, function and cartilage volume \[[@B66-ijms-21-01582],[@B67-ijms-21-01582]\]. These effects on cartilage may be, at least partially, ascribed to those protective molecules and miRNAs we found in the ASC secretome. In fact, three out of four of the most abundantly secreted factors (FST, TIMP2 and SERPINE1) are connected with extracellular matrix assembly and homeostasis and are further reported to have a direct influence on cartilage. TIMPs can regulate ECM remodeling and the activities of growth factors and their receptors by inhibiting MMPs \[[@B68-ijms-21-01582]\]. In dogs, *TIMP2* expression is decreased in OA cartilage \[[@B69-ijms-21-01582]\] and synovial fluids \[[@B70-ijms-21-01582]\], whereas, in mice, *TIMP2* depletion leads to accelerated OA \[[@B71-ijms-21-01582]\]. Similar protective effects on cartilage homeostasis were demonstrated in mice for the activin receptor follistatin, whose injection reduced both proteoglycan erosion and synovial macrophage infiltration \[[@B72-ijms-21-01582]\]. Further, Serpin E1, also called PAI-1 or plasminogen activator inhibitor 1, positively correlates with the synthesis of cartilage during pathophysiologic processes \[[@B73-ijms-21-01582]\] and counteracts the activity of urokinase/tissue-type plasminogen activators (uPA/tPA), both elevated in OA cartilage in contrast to reduced serpin E1 \[[@B74-ijms-21-01582]\]. Moreover, the presence of the urokinase plasminogen activator surface receptor (PLAUR) in the secretome (2.4 ng per 10^6^ ASCs) may also contribute to reduce plasminogen (either naturally occurring or secretome-shuttled) activation in plasmin, which can activate MMPs and plays an important role in modulating cartilage function \[[@B75-ijms-21-01582]\]. Furthermore, elafin (PI3) that was found in the secretome at 12 ng per million ASCs may directly inhibit MMP9 \[[@B76-ijms-21-01582]\].

Nevertheless, other abundant molecules, although at lower levels (between 10 and 100 ng with the exception of IGFBP4), have detrimental or ambiguous effects on cartilage homeostasis, making an overall potency prediction less straight-forward. IGFBPs (insuline growth factor-binding proteins) bind chondrocyte-secreted IGF-1, which induces the production of cartilage matrix components and has a protective role in OA \[[@B77-ijms-21-01582]\]. Accordingly, IGF-1 deficiency, partly caused by IGFPBs seizure, caused an increased severity of OA articular cartilage lesions in both rats and guinea pigs \[[@B78-ijms-21-01582],[@B79-ijms-21-01582]\]. Additionally, cathepsin S is a cysteine protease which has been implicated in the pathogenesis of OA and is involved in acute inflammatory conditions of cartilage \[[@B80-ijms-21-01582]\]. Interestingly, Dkk1, a Wnt pathway suppressor, was reported to have dual activity: its supplementation has been shown to protect mice from experimental OA \[[@B81-ijms-21-01582]\], whereas, in rats, the silencing alleviated chondrocyte apoptosis and cartilage destruction \[[@B82-ijms-21-01582]\]. Thus, a stringent control over Wnt-signaling is required to maintain cartilage homeostasis \[[@B83-ijms-21-01582]\]. Further, interleukin 6 is associated with increased levels of MMPs, as well as with the radiographic severity of OA \[[@B84-ijms-21-01582]\]; although, in the secretome, the concomitant presence of its receptor IL6ST may mitigate the detrimental effects. Similarly, the detection of receptors such as IL2RB and TNFRSF1A, with TNFRSF1B/11B and IL1RL1 and CD40 between 1 and 10 ng, may reduce the amount of free OA-related cytokines and chemokines \[[@B85-ijms-21-01582]\]. Thus, the global message of ASC-secreted factors supports the protective and postulated pro-regenerative effects observed in the clinical experience.

This indication is also endorsed by the EV-miRNAs. It clearly emerged that only a sharp definition of the disease context may allow a potency prediction. In fact, each miRNA may target multiple mRNAs which may be absent, weakly expressed or very abundant. In this work, we decided to study the effect of shuttled miRNAs on highly expressed transcripts, in either cartilage or macrophages, being aware that those with low levels might also have important direct regulatory or, through their protein products, active functions. Interestingly, EV-miRNAs appeared to regulate several processes connected with both OA-related transcriptional cascades and migration/cell motility. In particular, the TGFB pathway was demonstrated to play multiple roles in the development, growth and maintenance of articular cartilage \[[@B86-ijms-21-01582]\]. EV-miRNAs appeared to potentially downregulate the TGFBR1/2 branch of the pathway, targeting in addition the downstream effectors SMAD3 and 4. This is of relevance, since TGFBR1 levels and activation correlated with aggrecan and collagen type II levels in human OA cartilage \[[@B87-ijms-21-01582]\]. Nevertheless, a clear picture is again difficult to be drawn, since SMAD5, effector of the alternative ALK1-dependent branch of the TGFB pathway and highly correlating with MMP-13 mRNA levels \[[@B87-ijms-21-01582]\], is also targeted by EV-miRNAs. Thus, the net effect of miRNAs on the protective TGFBR1/Smad2/3 vs. destructive ALK1/Smad1/5 signaling balance may not be evaluable in silico. Under a different point of view, a tight regulation of TGFB may be beneficial, since its supplementation as a therapeutic agent, although leading to prolonged elevation of proteoglycan synthesis and content in articular cartilage, may also induce inflammation, synovial hyperplasia and osteophyte formation \[[@B88-ijms-21-01582]\]. Therefore, ASC-EVs might be an interesting adjuvant therapy to circumvent the undesirable effects of TGFB on cartilage repair. On the contrary, in silico-predicted effects on chondrocyte movements are much sharper, with a strong target on genes involved in cell motility and chemotactic response. Interestingly, in OA cartilage, it has been postulated that chondrocytes may move towards one another and cluster together \[[@B89-ijms-21-01582]\] to secrete inflammatory factors like TNF-α or IL-6. Thus, ASC-EVs could suppress chondrocyte movement and cluster formation observed in pathologic tissues. Eventually, miRNAs effects get even clearer when only those directly involved in cartilage protective or destructive mechanisms are considered ([Figure 7](#ijms-21-01582-f007){ref-type="fig"}). The net weight of shuttled miRNAs is toward protection, especially counteracting inflammatory signals. In particular, miR-24-3p represents 19% of EV-miRNAs and was proposed as therapeutic, since its reduction led to p16INK4a increase and MMP1 secretion, indicating that miR-24-3p is protective against senescence and cartilage catabolism \[[@B90-ijms-21-01582]\]. Additionally, miR-24-3p inhibits chondrocyte apoptosis and helps in reducing OA pathogenic processes in rats \[[@B91-ijms-21-01582]\]. In addition, among the most abundant ones, miR-125b-5p (12.5%) prevents aggrecan loss and miR-222-3p (5.8%) cartilage degradation. Therefore, in agreement with secreted factors, miRNAs have a strong balance towards protective messages on OA cartilage, although few degenerative signals may be identified.

Recently, together with cartilage repair \[[@B57-ijms-21-01582]\], MFAT was also demonstrated to mediate the activity of synovial macrophages \[[@B32-ijms-21-01582]\]. In fact, MFAT released mediators with long-lasting anti-inflammatory properties, unraveling the deep interplay with the OA synovial membrane and/or inflammatory cells presence/homeostasis. Supporting this paradigm, herein reported data showed a clear effect of ASCs factors and miRNAs. In fact, 23 secreted molecules control, at different levels, leukocyte chemotaxis, and 16 are involved with positive regulation. Among the most expressed, the alpha chemokine CXCL10, naturally present in OA synovial fluid, has a pivotal role in the first wave of leukocyte recruitment to the synovium \[[@B92-ijms-21-01582]\]. Of note, CXCL10 was also shown to effectively recruit human subchondral progenitors, suggesting that postulated purely inflammatory molecules may contribute to the migratory effect of synovial fluid, not only on inflammatory cells but also on human subchondral progenitors with healing properties \[[@B93-ijms-21-01582]\]. Similar properties on mesenchymal progenitors were shown for the neutrophil chemoattractant CXCL5, also found at \> 10 ng, and T cells-attractant CXCL12, able to enhance the migration of bone marrow MSCs \[[@B94-ijms-21-01582],[@B95-ijms-21-01582]\]. In contrast, CCL2 (\> 10 ng) does not recruit human MSCs \[[@B96-ijms-21-01582]\], being a potent soluble mediator involved in macrophage chemotaxis and migration together with other beta chemokines found in ASC secretome as CCL5/8 (\> 1 ng), CCL1/3/7/13/21 and MIF (\< 1 ng) \[[@B96-ijms-21-01582]\]. Intriguingly, and supporting the effectiveness of the herein proposed in vitro model, MSCs treated with OA synovial fluid showed high expression of CCL2 and IL6 \[[@B97-ijms-21-01582]\], that, together with migration, can direct M2 polarization of monocyte/macrophages \[[@B98-ijms-21-01582]\], suggesting not only an attractant but also a potential anti-inflammatory mechanism. In fact, once monocyte/macrophage accumulate within the inflamed synovial joints as the initial and critical step for OA pathogenesis, their survival, activation and, most importantly, polarization are crucial. In this path, TGFB, CSF1 and IL13 are potent stimulator of the M2 phenotype. They can explain, at least in part, how MSCs facilitate the monocyte to macrophage transition, attenuate already activated M1 macrophages and enhance M2 activation. In this frame, in previous reports, bone marrow MSCs promoted changes in the M1/M2 balance in vitro \[[@B99-ijms-21-01582]\]. This paradigm may also explain the in vitro observation that both ASCs and SVF induced macrophage polarization toward a pro-wound healing M2 type \[[@B100-ijms-21-01582]\]. Therefore, thanks to secreted factors, ASCs in enriched tissues as MFAT or SVF can attenuate M1 macrophages by shifting them to an M2 state, laying the foundations for injury resolution in inflammatory-stimulating environments, such as OA joints.

Intriguingly, in the last years, not only MSCs but also their purified EVs showed similar effects on macrophages with cartilage restoration, pain reduction and a M1 to M2 polarization \[[@B27-ijms-21-01582],[@B28-ijms-21-01582],[@B29-ijms-21-01582]\]. Mining the transcriptome of OA synovia-isolated macrophages, although EV-miRNAs targeted the macrophage-secreted remodeling enzymes, such as MMP1/3/9, they did not directly target and shutdown M1 signals. Albeit, they appeared to induce M2 polarization by interfering with TLR4, which suppresses STAT3, whose predominance over STAT1 increases M2 phenotype \[[@B101-ijms-21-01582]\]. This capacity was emphasized for miRNAs involved in M1 vs. M2 macrophage polarization \[[@B48-ijms-21-01582]\]. Twenty-six percent of miRNA molecules embedded in ASC-EVs are directly involved in M2 regulation ([Table 4](#ijms-21-01582-t004){ref-type="table"}). Although less in number with respect to M1 miRNAs, the presence of miR-24-3p and miR-222-3p (5.8%) tipped the balance towards a protective phenotype. In particular, miR-24-3p was reported to have a wide field of action in macrophages. First, it is able to mediate the transition between M1 and M2 states through p110δ \[[@B102-ijms-21-01582]\]. Second, it enhanced the ability of IL-4 and IL-13, both found in ASC secretome, to generate a M2 phenotype eventually able to resist M1 re-conversion under inducing stimuli \[[@B102-ijms-21-01582]\]. Third, miR-24-3p is a negative regulator of TLR-mediated pro-inflammatory cytokine production in M1 macrophages \[[@B103-ijms-21-01582],[@B104-ijms-21-01582]\]. Furthermore, miR-222-3p was demonstrated to suppress the expression of SOCS3, an alternative negative regulator of the M2 promoter STAT3 \[[@B105-ijms-21-01582]\]. Remarkably, ingenuity pathway analysis of the CCR5 signaling in macrophages identified JUN, FOS and MAP2K4 kinases as targets, suggesting an EV-dependent downregulation of the CCR5 cascade, whose inactivation resulted in a switch towards an M2 phenotype \[[@B49-ijms-21-01582]\]. Eventually, EV-miRNAs also target genes of the negative regulation of programmed cell death (GO:0043069) and of the apoptotic process (GO:0043066). This means that cell death and turnover might be tightly regulated in macrophages, being thus a further beneficial effect since, in mice, unbiased macrophage depletion did not attenuate the severity of OA but induced systemic inflammation with a massive infiltration of inflammatory T cells and neutrophils into the injured joints \[[@B106-ijms-21-01582]\]. Therefore, not only macrophage polarization but also the maintenance of specific macrophage subtypes, may be necessary to mitigate inflammation and OA.

Thus, being aware that other factors and EV-embedded miRNAs secreted by ASCs were not assayed in the present study and will need further characterization in future experiments, the global message of ASC secretome with a strong contribution of highly secreted TIMP1, TIMP2, PLG and CTSS or miR-24-3p, miR-222-3p and miR-193b-3p supports the protective and postulated pro-regenerative effects observed in the clinical experience and could be potential therapeutic candidates in organ/tissue healing.

4. Materials and Methods {#sec4-ijms-21-01582}
========================

4.1. Ethics Statement {#sec4dot1-ijms-21-01582}
---------------------

The research was performed at IRCCS Istituto Ortopedico Galeazzi under Institutional Review Board approval (San Raffaele Hospital Ethics Committee approval in date 8 March 2018, registered under number 6/int/2018). Specimens were collected after obtainment of patient informed consent (CI_REGAIN_adulto_v2) and following the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

4.2. Adipose-Derived Mesenchymal Stem Cell (ASCs) Isolation and Expansion {#sec4dot2-ijms-21-01582}
-------------------------------------------------------------------------

Adipose waste material from four female donors (ASC 1---57 yo, ASC 2---45 yo, ASC 3---54 yo and ASC 4---61 yo) undergoing liposuction was collected. Tissue was digested with type I collagenase (0.075% *w*/*v*, 30 min at 37 °C) (Worthington Biochemical Co, Lakewood, NJ, USA), filtered through a 100 μm cell strainer and centrifuged (1000 × g, 5 min). Pellets were suspended in DMEM + 10% FBS (GE Healthcare, Piscataway, NJ, USA) and penicillin-streptomycin (Life Technology, Carlsbad, CA, USA) and seeded at 5 × 10^3^ cells/cm^2^ in. Cells were cultured at 37 °C, 5% CO~2~ and 95% humidity and analyzed at passage 5 at 90% confluence after five times washed with PBS and eventual addition of FBS-free DMEM for 48 h. Inflammation was performed supplementing FBS-free DMEM with TNFα (5 pg/mL) + IL1β (10 pg/mL) + IFNγ (40 pg/mL) (Peprotech, London, UK), concentrations obtained calculating the median values from \[[@B32-ijms-21-01582],[@B33-ijms-21-01582],[@B34-ijms-21-01582],[@B35-ijms-21-01582],[@B36-ijms-21-01582],[@B37-ijms-21-01582],[@B38-ijms-21-01582],[@B39-ijms-21-01582],[@B40-ijms-21-01582]\]. Conditioned medium (secretome) was collected and centrifuged at 1000× *g* for 15 min at 4 °C, 2000× *g* for 15 min at 4 °C and twice at 4000× *g* for 15 min at 4°C. Clarified supernatant was split and used for EVs analysis and ELISA assays. At time of supernatant collection, cells were detached, counted and viability assessed with Tali image-based cytometer (Thermo Fisher Scientific, Waltham, MA, USA).

4.3. ASCs Flow Cytometry Characterization {#sec4dot3-ijms-21-01582}
-----------------------------------------

Flow cytometry was used to score positive or negative MSC (CD44-PE Vio770 clone REA690, CD73-PE clone REA804 and CD90-FITC clone REA897) or hemato/endothelial (CD34-FITC clone AC136, CD31-PerCp Vio700 clone REA730 and CD45-PE Vio770 clone REA747) (Miltenyi Biotec, Bergisch Gladbach, Germany) markers with a CytoFLEX flow cytometer (Beckman Coulter, Fullerton, CA, USA) collecting a minimum of 10,000 events. Doublets and cell aggregates were removed from analysis gating events on FSC-A and FSC-H plots.

4.4. ELISA Assays {#sec4dot4-ijms-21-01582}
-----------------

Concentrations of 200 soluble cytokines, chemokines, receptors and inflammatory and growth factors were determined by Quantibody^®^ Human Cytokine Array 4000 Kit (<https://www.raybiotech.com/quantibody-human-cytokine-array-4000/>) in the ASC secretomes after, according to the manufacturers' instructions (RayBiotech, Norcross, GA, USA). Dilutions (1:2) allowed to have absorbance readings within the standard curve values. The amount of each factor in pg/mL was converted into pg/million cells by multiplying the original value for the total volume in ml and, finally, diving by the total number of cells. Values are shown as million cells normalized pg and mean values ± SD calculated.

4.5. EVs Isolation and Characterization {#sec4dot5-ijms-21-01582}
---------------------------------------

Five milliliters of clarified secretomes were 1:2 diluted with PBS and centrifuged at 100,000× *g* for 9 h at 4 °C in a 70Ti rotor (Beckman Coulter, Fullerton, CA, USA), and EV pellets were processed as follows:(i)Flow cytometry: Before ultracentrifugation, secretomes were additioned with 10 µM CFSE (Sigma-Aldrich) and incubated for 1 h at 37 °C. After ultracentrifugation, as previously described, labelled EVs were suspended in 50 µl PBS per 5 mL of processed medium. Particles were 1:10,000 diluted in PBS and 100 µl stained with anti-5 μL CD9-APC clone HI9a, anti-CD63-APC clone H5C6 and CD81-APC clone 5A6 (Biolegend, San Diego, CA, USA) for 30 min at 4 °C in the dark. Antibodies were used individually. Events collection was performed with a CytoFLEX flow cytometer collecting a minimum of 30,000 events. A reference bead mix (Biocytex, Marseille, France) composed of a FITC fluorescent mixture of spheres (100 nm, 300 nm, 500 nm and 900 nm) was used to set up the flow cytometer. Gains were: FSC = 106, SSC = 61, FITC = 272, PE = 116 and PC7 = 371. FITC threshold was set at 500 to include 100 nm beads and some smaller debris in the FITC channel.(ii)Transmission electron microscopy: Five microliters of PBS-suspended EVs were absorbed on Formvar carbon-coated grids for 10 min. Filter paper was used to blot drops. Negative stain was performed with 2% uranyl acetate aqueous suspension for 10 min, and excess was removed by filter paper before drying the grid at RT. Samples were examined with a TALOS L120C transmission electron microscope (Thermo Fisher Scientific, Waltham, MA, USA) at 120 kV.(iii)Nanoparticle tracking analysis (NTA): Purified EVs in PBS (1:100 diluted) were visualized by Nanosight LM10-HS system (NanoSight Ltd., Amesbury, UK). Three recordings of 30 s were performed for each sample. NTA software was used to analyze the data and provided both the concentration measurements and the high-resolution particle size distribution profiles.

4.6. Screening of EV-Embedded miRNA Expression {#sec4dot6-ijms-21-01582}
----------------------------------------------

After ultracentrifugation, Trizol was used to dissolve EV pellets, and miRNeasy Kit and RNeasy CleanUp Kit were used sequentially to obtain RNA enriched in small molecules \< 200 nt (Qiagen, Hilden, Germany). During extraction, 6 pg of a nonhuman synthetic miRNA (arabidopsis thaliana ath-miR-159a) were added to each sample as a spike-in to monitor the technical variability during both the isolation and the following reactions. The spike-in was further used to equalize A and B panels of the OpenArray^®^ platform (Life Technologies). Briefly, cDNAs were prepared by standard reverse transcription (RT), and preamplification was performed with A and B independent kits, followed by real-time RT-PCR analysis with the QuantStudio™ 12 K Flex OpenArray^®^ Platform (QS12KFlex), as previously described \[[@B107-ijms-21-01582]\]. To process miRNA expression data from the A and B miRNA panels, together covering 754 human miRNA sequences from the Sanger miRBase v21 Gene, the Expression Suite Software (Life Technologies) was used. C~RT~ of 28 was considered as a burden for the absence or presence of amplification. The global mean was selected as a normalization method \[[@B108-ijms-21-01582]\] and was calculated from miRNAs positively amplified in all samples. Normalized miRNA expression was determined using the relative quantification 2−Δ^C^~RT~. Values are shown as normalized Ct and mean values ± SD calculated.

4.7. Pathway Analysis {#sec4dot7-ijms-21-01582}
---------------------

Identification of functional annotations:(i)Protein: Secretome-identified factors were subjected to functional enrichment analysis to provide insight into the functional associations of these protein subsets. The analysis was performed using Gorilla tool (<http://cbl-gorilla.cs.technion.ac.il/>) with two unranked lists of genes (target and background lists) running mode and 200 factors of the ELISA array as background \[[@B109-ijms-21-01582],[@B110-ijms-21-01582]\]. The list of proteins was also submitted to the PANTHER web interface (<http://www.pantherdb.org/>) to identify proteins belonging to the same functional classifications, following default settings \[[@B111-ijms-21-01582]\].(ii)miRNA: The predicted miRNA targets were annotated into functional BP using the microRNA Target Filter tool in ingenuity pathway analysis (IPA; Ingenuity^®^ Systems, <http://www.ingenuity.com>). Filters were: confidence "experimentally observed", with all sources available in the IPA database (TarBase, miRecords, TargetScan Human and Ingenuity Expert Findings). To obtain the list of all experimentally validated mRNA targets, no disease filter was set.

4.8. Hierarchical Clustering {#sec4dot8-ijms-21-01582}
----------------------------

Heat map plots were generated, scoring factors or miRNAs with ClustVis package (<https://biit.cs.ut.ee/clustvis/>) \[[@B112-ijms-21-01582]\]. Clustering options were: distance for rows---correlation, method for rows---average and tree ordering for rows---tightest cluster first. Log~2~ \[(pg) factors per 10^6^ cells\] or miRNA C~RT~ after normalization values were used.

4.9. Statistical Analyses {#sec4dot9-ijms-21-01582}
-------------------------

In each experiment, four independent ASCs were analyzed. Only proteins or miRNAs present and quantified in all conditions were considered as positively identified. GraphPad Prism software (GraphPad, San Diego, CA, USA) was used for statistical analysis. Kolmogorov--Smirnov normality test assayed normal data distribution. Grubbs' test identified outliers. The level of significance was set with a minimum *p*-value \< 0.05. Data was presented as mean ± SD ([Appendix A](#app2-ijms-21-01582){ref-type="app"}).

5. Conclusions {#sec5-ijms-21-01582}
==============

Secreted factors and EV-embedded miRNAs may explain the promising results observed for both expanded ASCs and ASC-enriched products as SVF or MFAT. Both molecules and miRNAs may profoundly alter cartilage homeostasis and macrophage polarization, supporting the protective and pro-regenerative effects observed in the clinical experience. We think that this report shed light on some mechanisms that mesenchymal stem cells, alone or in their niche, activate to heal a diseased joint. Future studies will be needed, especially under the light of new transcriptomes being daily released for the other cellular players, as the identification of the targets appeared as a mandatory sieve to deeply understand cellular and molecular interactions.
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![Surface marker expressions of adipose-derived MSCs (ASCs). After FSC/SSC gating and doublets removal (**A**), ASCs without and with osteoarthritis (OA) inflammation resulted positive for CD90/73/44 MSC markers (**B**) and negative for CD34/31/45 hemato/endothelial determinants (**C**). Red: unstained ASCs, green: stained ASCs and blue: stained inflamed (OA) ASCs. Representative cytograms of a single population are shown.](ijms-21-01582-g001){#ijms-21-01582-f001}

![Heat map of ASCs-secreted factors across all samples. Heat map of hierarchical clustering analysis: the log~2~ values of 75 detected secreted factors after normalization per 10^6^ ASCs. The sample clustering tree is shown at the top. The color scale shown in the map illustrates the absolute expression levels of factors across all samples: red shades = high expression levels (high log~2~(pg) per 10^6^ ASCs) and blue shades = lower expression levels (low log~2~(pg) per 10^6^ ASCs).](ijms-21-01582-g002){#ijms-21-01582-f002}

![A visualization of the biological process gene ontology annotations using Gorilla for identified secreted factors. **A**) The background dataset used is composed of 200 human factors tested in the ELISA arrays (see Materials and Methods). Enrichment using the 18 factors expressed at \> 10 ng per 10^6^ ASCs is shown. **B**) Enrichment using the 57 factors expressed at \< 10 ng per 10^6^ ASCs is shown. The Gorilla settings were left at default values: *p*-value threshold of *p* \< 10^−3^, organism Homo sapiens.](ijms-21-01582-g003){#ijms-21-01582-f003}

![Characterization of ASC-EVs (extracellular vesicles). **A**) Transmission electron micrographs of ASC-EVs showing particles with characteristic cup-shaped morphology. **B**) Size distribution of nanoparticles by NanoSight particle-tracking analysis. **C**) Nanometric fluorescent beads with diameters of 100 nm, 300 nm, 500 nm and 900 nm used for flow cytometer calibration confirmed instrument sensitivity with respect to background. **D**) CFSE-stained ASC-EVs (green) with respect to background. **E**) Flow cytometry scoring CD63/81 EV marker positivity on CFSE-labeled ASC-EVs. CD9 resulted barely positive. One representative donor is shown.](ijms-21-01582-g004){#ijms-21-01582-f004}

![Heat map of EV-miRNAs across all samples. Heat map of hierarchical clustering analysis of the normalized C~RT~ values of detected miRNAs in ASC-EVs. Rows are centered. The sample clustering tree is shown at the top. The color scale shown in the map illustrates the absolute expression levels of factors across all samples: red shades = high expression levels (low C~RT~ values) and blue shades = lower expression levels (high C~RT~ values).](ijms-21-01582-g005){#ijms-21-01582-f005}

![A visualization of the biological process gene ontology annotations using Gorilla for targets of abundant EV-miRNAs. The background dataset used is composed of the entire human genome. Enrichment using the 818 mRNAs verified as targets of EV-miRNAs in the first quartile of expression. The Gorilla settings were left at default values: *p*-value threshold of *p* \< 10^−6^, organism Homo sapiens.](ijms-21-01582-g006){#ijms-21-01582-f006}

![EV-miRNAs involved in protective or destructive mechanisms in the OA joint. Indication of miRNAs in the first quartile of expression in ASC-EVs and their role in cartilage homeostasis. miRNAs are divided per category and the relative amount of their genetic message shown.](ijms-21-01582-g007){#ijms-21-01582-f007}

![EV-miRNAs involved in M1 or M2 polarization in macrophages. Indication of miRNAs in the first quartile of expression in ASC-EVs and their role in macrophage polarization. miRNAs are divided per category, and the relative amount of their genetic message is shown. Direction of arrows represents the guidance of polarization phenotype. Size of arrows reflects the genetic weight.](ijms-21-01582-g008){#ijms-21-01582-f008}
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pg per 10^6^ adipose-derived MSCs (ASCs) in 48 h.

  FACTOR      ASC 1       ASC 2       ASC 3     ASC 4       MEAN        SD        DESCRIPTION
  ----------- ----------- ----------- --------- ----------- ----------- --------- -------------------------------------------------------
  FST         1,492,673   1,081,479   570,416   1,004,932   1,037,375   377,865   Follistatin
  TIMP2       167,790     162,350     198,481   256,519     196,285     43,191    Metalloproteinase inhibitor 2
  IGFBP4      223,536     276,754     145,198   84,223      182,428     84,887    Insulin-like growth factor-binding protein 4
  SERPINE1    109,335     103,661     98,032    119,475     10,7626     9148      Plasminogen activator inhibitor 1
  IGFBP6      86,610      83,502      77,842    94,332      85,572      6877      Insulin-like growth factor-binding protein 6
  IL6ST       68,647      68,361      36,585    50,182      55,944      15,530    Interleukin-6 receptor subunit beta
  CTSS        52,275      50,380      40,226    64,808      51,922      10,089    Cathepsin S
  IL6         43,025      30,591      40,435    82,769      49,205      23,008    Interleukin-6
  TIMP1       34,985      27,024      33,210    41,839      34,265      6094      Metalloproteinase inhibitor 1
  ICAM1       28,715      21,857      22,377    33,311      26,565      5472      Intercellular adhesion molecule 1
  CXCL10      28,629      21,386      16,094    38,665      26,193      9774      C-X-C motif chemokine 10
  IL2RB       28,885      20,962      18,101    27,057      23,751      5066      Interleukin-2 receptor subunit beta
  TNFRSF1A    15,652      21,277      21,328    13,791      18,012      3875      Tumor necrosis factor receptor superfamily member 1A
  CCL2        16,286      13,411      15,771    19,076      16,136      2325      C-C motif chemokine 2
  PLG         17,218      14,055      14,936    17,793      16,001      1790      Plasminogen
  CXCL5       15,226      5628        5204      36,614      15,668      14,711    C-X-C motif chemokine 5
  DKK1        17,275      12,422      8703      9540        11,985      3870      Dickkopf-related protein 1
  PI3         18,953      3218        6567      20,207      12,236      8605      Elafin (Peptidase inhibitor 3)
  CCL5        15,611      4502        4407      11,970      9122        5591      C-C motif chemokine 5
  FLT1        5604        4854        13,916    10,834      8802        4324      Vascular endothelial growth factor receptor 1
  IGFBP3      4898        11,609      5145      11,349      8250        3731      Insulin-like growth factor-binding protein 3
  ANG         4612        8990        5615      2158        5344        2831      Angiogenin
  SHH         6957        5751        3445      5437        5398        1457      Sonic hedgehog protein
  GDF15       5128        6376        4534      4167        5051        968       Growth/differentiation factor 15
  CXCL9       4391        2472        1272      10,677      4703        4185      C-X-C motif chemokine 9
  CSF1        4488        3510        3624      2797        3604        693       Macrophage colony-stimulating factor 1
  CXCL1       3334        3781        2516      4276        3477        747       Growth-regulated alpha protein
  IL1RL1      5212        1440        3249      3991        3473        1579      Interleukin-1 receptor-like 1
  TNFRSF11B   4378        1861        4234      2934        3352        1187      Tumor necrosis factor receptor superfamily member 11B
  CXCL8       2521        3046        2715      3839        3030        581       Interleukin-8
  TNFRSF1B    2277        3327        1014      5025        2911        1697      Tumor necrosis factor receptor superfamily member 1B
  VEGFA       1956        2378        1738      5600        2918        1808      Vascular endothelial growth factor A
  PLAUR       2404        3497        2581      1114        2399        981       Urokinase plasminogen activator surface receptor
  CSF3        1989        897         770       6605        2565        2748      Granulocyte colony-stimulating factor
  CCL8        1107        2046        1098      3351        1900        1064      C-C motif chemokine 8
  CCL4        1851        1055        1312      2689        1727        722       C-C motif chemokine 4
  CD40        1730        1681        841       1380        1408        408       Tumor necrosis factor receptor superfamily member 5
  CD14        1467        2114        1175      555         1328        648       Monocyte differentiation antigen CD14
  EGFR        1006        1602        792       1938        1335        529       Epidermal growth factor receptor
  AXL         958         2294        1183      277         1178        838       Tyrosine-protein kinase receptor UFO
  TREM1       961         1063        709       1549        1071        352       Triggering receptor expressed on myeloid cells 1
  TYRO3       2334        123         1155      494         1026        971       Tyrosine-protein kinase receptor TYRO3
  HGF         823         832         1407      778         960         299       Hepatocyte growth factor
  LIF         676         834         1014      1295        954         265       Leukemia inhibitory factor
  CXCL16      514         1256        539       993         825         362       C-X-C motif chemokine 16
  CXCL6       1144        546         41        1123        714         527       C-X-C motif chemokine 6
  NRCAM       574         723         50        1424        693         567       Neuronal cell adhesion molecule
  CCL21       731         1164        384       289         642         397       C-C motif chemokine 21
  TGFB1       769         793         630       363         639         197       Human TGF-beta 1
  SPP1        189         434         635       917         544         308       Osteopontin
  TNFRSF10D   637         103         330       1033        526         403       Tumor necrosis factor receptor superfamily member 10D
  FAS         608         399         540       203         438         179       Tumor necrosis factor receptor superfamily member 6
  FGF7        617         308         575       208         427         200       Fibroblast growth factor 7
  SIGLEC5     456         545         288       446         434         107       Sialic acid-binding Ig-like lectin 5
  IL23A       441         425         166       655         422         200       Interleukin-23 subunit alpha
  IL17B       532         453         438       156         395         164       Interleukin-17B
  MIF         376         285         446       479         396         86        Macrophage migration inhibitory factor
  CCL1        88          112         73        1214        371         562       C-C motif chemokine 1
  CD40LG      80          268         220       588         289         215       CD40 ligand
  CCL13       166         155         297       490         277         156       C-C motif chemokine 13
  VEGFC       568         215         160       23          241         232       Vascular endothelial growth factor C
  CCL11       159         103         416       294         243         141       Eotaxin
  IL1B        271         179         187       294         233         58        Interleukin-1 beta
  TNF         81          123         151       590         236         237       Tumor necrosis factor
  ENG         162         128         254       179         181         53        Endoglin
  TNFRSF21    62          199         76        192         132         73        Tumor necrosis factor receptor superfamily member 21
  CCL7        58          72          54        362         137         150       C-C motif chemokine 7
  CCL3        90          19          25        251         96          108       C-C motif chemokine 3
  IL2RA       108         74          72        58          78          21        Interleukin-2 receptor subunit alpha
  AGRP        17          125         16        113         68          59        Agouti-related protein
  IL1A        85          25          26        115         63          45        Interleukin-1 alpha
  CXCL12      71          92          19        28          52          35        Stromal cell-derived factor 1
  IL17A       87          1           34        78          50          40        Interleukin-17A
  PGF         25          8           20        100         38          42        Placenta growth factor
  IL13        18          9           11        25          16          7         Interleukin-13

Colors represent factor amount, red for high and blue for low.
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###### 

Enriched gene ontology (GO) terms for secreted factors.

  Factor Amount        GO TERM                                            Description                       *p*-Value                                                                                                                                                                                                   Factors
  -------------------- -------------------------------------------------- --------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  \> 10 ng/10^6^ ASC   GO:0022411                                         cellular component disassembly    3.74 × 10^−6^                                                                                                                                                                                               TIMP1, TIMP2, DKK1, PLG and CTSS
  GO:0022617           extracellular matrix disassembly                   5.13 × 10^−5^                     TIMP1, TIMP2, PLG and CTSS                                                                                                                                                                                  
  \< 10 ng/10^6^ ASC   GO:0002791                                         regulation of peptide secretion   8.05 × 10^−4^                                                                                                                                                                                               IL17A, ANG, VEGFC, TGFB1, CCL5, IL13, IL1RL1, MIF, CD40LG, IL1B, CD40, CCL1, IL1A, CCL3, TNFRSF21, TNF, EGFR, CD14 and TNFRSF1B
  GO:0050708           regulation of protein secretion                    8.05 × 10^−4^                     IL17A, ANG, VEGFC, TGFB1, CCL5, IL13, IL1RL1, MIF, CD40LG, CCL1, CD40, IL1B, IL1A, CCL3, TNFRSF21, TNF, EGFR, CD14 and TNFRSF1B                                                                             
  GO:0022603           regulation of anatomical structure morphogenesis   8.07 × 10^−4^                     SHH, FLT1, CXCL9, GDF15, LIF, PGF, CXCL12, SPP1, FGF7, ENG, CSF1, VEGFA, CCL13, VEGFC, CCL11, TGFB1, CCL8, CCL7, IL1B, CD40, IL1A, CCL3, HGF, TNF, IL8, TNFRSF1B, NRCAM and TNFSRSF11B                      
  GO:0043903           regulation of symbiosis                            8.22 × 10^−4^                     TNF, IL8, CCL5, CCL4, CCL8, CXCL6 and CCL3                                                                                                                                                                  
  GO:0070201           regulation of protein localization                 9.16 × 10^-4^                     IL17A, ANG, VEGFC, TGFB1, SHH, CCL5, IL13, IL1RL1, MIF, CD40LG, CCL1, IL1B, CD40, IL1A, CCL3, TNFRSF21, TNF, EGFR, CD14 and TNFRSF1B                                                                        
  GO:0051223           regulation of protein transport                    9.16 × 10^−4^                     IL17A, ANG, VEGFC, TGFB1, SHH, CCL5, IL13, IL1RL1, MIF, CD40LG, IL1B, CD40, CCL1, IL1A, CCL3, TNFRSF21, TNF, EGFR, CD14 and TNFRSF1B                                                                        
  GO:0090087           regulation of peptide transport                    9.16 × 10^−4^                     IL17A, ANG, VEGFC, TGFB1, SHH, CCL5, IL13, IL1RL1, MIF, CD40LG, CCL1, CD40, IL1B, IL1A, CCL3, TNFRSF21, TNF, EGFR, CD14 and TNFRSF1B                                                                        
  GO:0006954           inflammatory response                              9.98 × 10^−4^                     IL17A, IL17B, CXCL9, IL13, MIF, SPP1, IL23A, AXL, CD14, CSF1, CCL13, CCL11, TGFB1, CCL5, IL2RA, CCL4, CCL8, CCL7, CD40LG, TREM1, IL1B, CD40, CCL1, IL1A, CCL3, TNF, CXCL1, IL8, CXCL6, TNFRSF1B and CCL21   
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###### 

First-quartile extracellular vesicle (EV)-miRNAs involved in osteoarthritis (OA) pathogenesis.

  Protective                                                                                                                   
  ----------------------------------- ------------------------- ---------------------------------- --------------------------- --------------------------------------------------------
  hsa-miR-24-3p                       19.0                      *P16INK4A*                         Cartilage                   Regulates senescence
  hsa-miR-222-3p                      5.8                       *HDAC4*                            Cartilage                   Prevents cartilage degradation
  hsa-miR-193b-3p                     5.0                       *TGFB2-3/MMP19*                    Cartilage                   Regulates inflammation
  hsa-miR-92a-3p                      1.5                       *ADAMTS4-5/HDAC2*                  Cartilage                   Anti-catabolic
  hsa-miR-29a-3p                      1.1                       *VEGF*                             Synovium                    Inhibits synovial remodeling
  hsa-miR-199a-3p                     0.9                       *COX2*                             Cartilage                   Anti-catabolic
  hsa-miR-27a-3p                      0.8                       *FSTL1*                            Synovium                    Prevents synoviocyte migration
  hsa-miR-26a-5p                      0.6                       *iNOS*                             Cartilage                   Cartilage homeostasis
  hsa-miR-130a-3p                     0.6                       *TNFa*                             Cartilage                   Anti-inflammatory
  hsa-miR-320a-3p                     0.5                       *BMI1/RUNX2/MMP13*                 Cartilage                   Chondrogenic
  hsa-miR-152-3p                      0.5                       *DNMT*                             Synovium                    Prevents synoviocyte migration
  hsa-miR-17-5p                       0.5                       *SQSTM1*                           Cartilage                   Induces Autophagy
  hsa-miR-27b-3p                      0.3                       *MMP13/LEPTIN*                     Cartilage                   Anti-catabolic
  hsa-miR-210-3p                      0.2                       *DR6/HIF3a*                        Cartilage                   Anti-apoptotic/promotes ECM
  hsa-miR-30a-5p                      0.2                       *ADAMTS5*                          Cartilage                   Cartilage homeostasis
  hsa-miR-26b-5p                      0.1                       *KPNA3*                            Cartilage                   Promotes NF-kB pathway
  hsa-miR-149-5p                      0.1                       *TNFa*                             Cartilage                   Anti-inflammatory
  **Total**                           **37.9**                                                                                 
  **Destructive**                                                                                                              
  **miRNA**                           **% EV-genetic weight**   **Target**                         **Tissue**                  **Role**
  hsa-miR-21-5p                       4.7                       *GDF5*                             Cartilage                   Chondrogenesis inhibitor
  hsa-miR-30b-5p                      2.4                       *BECN1/ATG5*                       Cartilage                   ECM degradation
  hsa-miR-19b-3p                      1.4                       *nd*                               Synovium                    Induces NF-kB signaling
  hsa-miR-34a-5p                      0.7                       *SIRT1*                            Cartilage                   Apoptotic
  hsa-miR-16-5p                       0.4                       *SMAD3*                            Cartilage                   Cartilage degradation
  hsa-miR-138-5p                      0.2                       *FOXC1*                            Cartilage                   Promotes cartilage degradation
  hsa-miR-483-5p                      0.1                       *MATN3/TIMP2*                      Cartilage                   ECM degradation
  **Total**                           **9.8**                                                                                  
  **Protective/[Destructive]{.ul}**                                                                                            
  **miRNA**                           **% EV-genetic weight**   **Target**                         **Tissue**                  **Role**
  hsa-miR-125b-5p                     12.6                      *ADAMTS4/* *[SYVN1]{.ul}*          Cartilage/[Synovium]{.ul}   Prevents aggrecan loss/[Pro-apoptotic]{.ul}
  hsa-miR-221-3p                      4.7                       *SDF1/* *[nd]{.ul}*                Cartilage                   Prevents ECM degradation/[Pro-inflammatory]{.ul}
  hsa-miR-145-5p                      1.7                       *TNFRSF11B/* *[SOX9-SMAD3]{.ul}*   Cartilage                   Chondrocyte proliferation/[Cartilage degradation]{.ul}
  hsa-miR-365-3p                      0.2                       *HIF2a/* *[HDAC4]{.ul}*            Cartilage                   Prevents ECM loss/[Pro-inflammatory]{.ul}
  **Total**                           **19.2**                                                                                 
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###### 

First-quartile EV-miRNAs involved in macrophage polarization.

  M1 Polarization                                 
  --------------------- ------------------------- ----------------------------------------
  hsa-miR-145-5p        1.7                       Promotes M1
  hsa-miR-27a-3p        0.8                       Promotes M1, suppresses M2
  hsa-miR-27b-3p        0.3                       Promotes M1, suppresses M2
  hsa-miR-130a-3p       0.6                       Promotes M1, suppresses M2
  hsa-miR-26a-5p        0.6                       Suppresses M2
  hsa-miR-26b-5p        0.1                       Suppresses M2
  hsa-miR-720           3.0                       Suppresses M2
  **Total**             **7.2**                   
  **M2 Polarization**                             
  **miRNAs**            **% EV-Genetic Weight**   **Regulation of Macrophage Phenotype**
  hsa-miR-34a-5p        0.7                       Promotes M2
  hsa-miR-222-3p        5.8                       Promotes M2
  hsa-let-7b-5p         0.6                       Promotes M2
  hsa-miR-24-3p         19.0                      Promotes M2, suppresses M1
  **Total**             **26.1**                  
